Feedback from the September share holder meeting provided by Yooper61 - Mgt said that B was embraced by the FDA. The fact the FDA has approved moving forward with P3, with such a modest sample size is impressive. The FDA is fine with the primary endpoint being high dose every 3 weeks. The trial size requested is 300 active drug recipients. They would go 2:1 drug:placebo, so 450 trial size.